Viatris Inc. or Travere Therapeutics, Inc.: Who Invests More in Innovation?

Viatris vs. Travere: A Decade of R&D Investment

__timestampTravere Therapeutics, Inc.Viatris Inc.
Wednesday, January 1, 201447795223581800000
Thursday, January 1, 201550426000671900000
Friday, January 1, 201670853000876700000
Sunday, January 1, 201778168000857900000
Monday, January 1, 2018123757000822200000
Tuesday, January 1, 2019140963000778200000
Wednesday, January 1, 2020131773000512600000
Friday, January 1, 2021210328000681000000
Saturday, January 1, 2022235780000662200000
Sunday, January 1, 2023244990000910700000
Loading chart...

Unleashing the power of data

Innovation Investment: Viatris Inc. vs. Travere Therapeutics, Inc.

In the competitive landscape of pharmaceuticals, innovation is key. Over the past decade, Viatris Inc. and Travere Therapeutics, Inc. have shown distinct strategies in their research and development (R&D) investments. From 2014 to 2023, Viatris consistently outpaced Travere, investing nearly three times more in R&D annually. In 2023, Viatris allocated approximately 910 million dollars, marking a 56% increase from 2014. Meanwhile, Travere's R&D spending grew by over 400%, reaching around 245 million dollars in 2023. This significant growth highlights Travere's commitment to innovation, despite its smaller scale. The data underscores a broader trend: while larger firms like Viatris maintain substantial R&D budgets, smaller companies like Travere are rapidly increasing their investments, potentially reshaping the industry's future. This dynamic shift in R&D spending patterns is crucial for stakeholders aiming to understand the evolving pharmaceutical landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025